Sarah C. Reed

Sarah C. Reed

Auto-generated profile, based on publicly available information

Sarah C. Reed

Medical Scientist Training Program, Vanderbilt University School of Medicine

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
VAViktor A. Adalsteinsson
Viktor A. Adalsteinsson
GHGavin Ha
Gavin Ha
SFSamuel S. Freeman
Samuel S. Freeman
ACAtish Choudhury
Atish Choudhury
DSDaniel G. Stover
Daniel G. Stover
MMMatthew Meyerson
Matthew Meyerson
Whole-exome sequencing of cell-free DNA (cfDNA) could enable comprehensive profiling of tumors from blood but the genome-wide concordance between cfDNA and tumor biopsies is uncertain. Here we report ichorCNA, software that quantifies tumor content in cfDNA from 0.1× coverage whole-genome sequencing data without prior knowledge of tumor mutations. We apply ichorCNA to 1439 blood samples from 520 patients with metastatic prostate or breast cancers. In the earliest tested sample for each patient, 34% of patients have ≥10% tumor-derived cfDNA, sufficient for standard coverage whole-exome sequencing. Using whole-exome sequencing, we validate the concordance of clonal somatic mutations (88%), copy number alterations (80%), mutational signatures, and neoantigens between cfDNA and matched tumor biopsies from 41 patients with ≥10% cfDNA tumor content. In summary, we provide methods to identify patients eligible for comprehensive cfDNA profiling, revealing its applicability to many patients, and demonstrate high concordance of cfDNA and metastatic tumor whole-exome sequencing.

1 June 2020 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
AZAsaf Zviran
Asaf Zviran
RSRafael C. Schulman
Rafael C. Schulman
MSMinita Shah
Minita Shah
SHSteven T. K. Hill
Steven T. K. Hill
SDSunil Deochand
Sunil Deochand
DLDan A. Landau
Dan A. Landau

1 July 2018 in Cell
Verified
Journal Article
Closed access
SVSrinivas R. Viswanathan
Srinivas R. Viswanathan
GHGavin Ha
Gavin Ha
AHAndreas M. Hoff
Andreas M. Hoff
JWJeremiah A. Wala
Jeremiah A. Wala
JCJian Carrot-Zhang
Jian Carrot-Zhang
MMMatthew Meyerson
Matthew Meyerson

1 January 2018 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
EPEirini Pectasides
Eirini Pectasides
MSMatthew D. Stachler
Matthew D. Stachler
SDSarah Derks
Sarah Derks
YLYang Liu
Yang Liu
SMSteven Maron
Steven Maron
Daniel VT CatenacciDaniel VT Catenacci
Daniel VT Catenacci
Gastroesophageal adenocarcinoma (GEA) is a lethal disease where targeted therapies, even when guided by genomic biomarkers, have had limited efficacy. A potential reason for the failure of such therapies is that genomic profiling results could commonly differ between the primary and metastatic tumors. To evaluate genomic heterogeneity, we sequenced paired primary GEA and synchronous metastatic lesions across multiple cohorts, finding extensive differences in genomic alterations, including discrepancies in potentially clinically relevant alterations. Multiregion sequencing showed significant discrepancy within the primary tumor (PT) and between the PT and disseminated disease, with oncogene amplification profiles commonly discordant. In addition, a pilot analysis of cell-free DNA (cfDNA) sequencing demonstrated the feasibility of detecting genomic amplifications not detected in PT sampling. Lastly, we profiled paired primary tumors, metastatic tumors, and cfDNA from patients enrolled in the personalized antibodies for GEA (PANGEA) trial of targeted therapies in GEA and found that genomic biomarkers were recurrently discrepant between the PT and untreated metastases. Divergent primary and metastatic tissue profiling led to treatment reassignment in 32% (9/28) of patients. In discordant primary and metastatic lesions, we found 87.5% concordance for targetable alterations in metastatic tissue and cfDNA, suggesting the potential for cfDNA profiling to enhance selection of therapy. Significance: We demonstrate frequent baseline heterogeneity in targetable genomic alterations in GEA, indicating that current tissue sampling practices for biomarker testing do not effectively guide precision medicine in this disease and that routine profiling of metastatic lesions and/or cfDNA should be systematically evaluated. Cancer Discov; 8(1); 37–48. ©2017 AACR. See related commentary by Sundar and Tan, p. 14. See related article by Janjigian et al., p. 49. This article is highlighted in the In This Issue feature, p. 1

20 February 2018 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
DSDaniel G. Stover
Daniel G. Stover
HPHeather A. Parsons
Heather A. Parsons
GHGavin Ha
Gavin Ha
SFSamuel S. Freeman
Samuel S. Freeman
WBWilliam T. Barry
William T. Barry
VAViktor A. Adalsteinsson
Viktor A. Adalsteinsson
Purpose: Cell-free DNA (cfDNA) offers the potential for minimally invasive genome-wide profiling of tumor alterations without tumor biopsy and may be associated with patient prognosis. Triple-negative breast cancer (TNBC) is characterized by few mutations but extensive somatic copy number alterations (SCNAs), yet little is known regarding SCNAs in metastatic TNBC. We sought to evaluate SCNAs in metastatic TNBC exclusively via cfDNA and determine if cfDNA tumor fraction is associated with overall survival in metastatic TNBC.Patients and Methods: In this retrospective cohort study, we identified 164 patients with biopsy-proven metastatic TNBC at a single tertiary care institution who received prior chemotherapy in the (neo)adjuvant or metastatic setting. We performed low-coverage genome-wide sequencing of cfDNA from plasma.Results: Without prior knowledge of tumor mutations, we determined tumor fraction of cfDNA for 96.3% of patients and SCNAs for 63.9% of patients. Copy number profiles and percent genome altered were remarkably similar between metastatic and primary TNBCs. Certain SCNAs were more frequent in metastatic TNBCs relative to paired primary tumors and primary TNBCs in publicly available data sets The Cancer Genome Atlas and METABRIC, including chromosomal gains in drivers NOTCH2, AKT2, and AKT3. Prespecified cfDNA tumor fraction threshold of ≥ 10% was associated with significantly worse metastatic survival (median, 6.4 v 15.9 months) and remained significant independent of clinicopathologic factors (hazard ratio, 2.14; 95% CI, 1.4 to 3.8; P < .001).Conclusion: We present the largest genomic characterization of metastatic TNBC to our knowledge, exclusively from cfDNA. Evaluation of cfDNA tumor fraction was feasible for nearly all patients, and tumor fraction ≥ 10% is associated with significantly worse survival in this large metastatic TNBC cohort. Specific SCNAs are enriched and prognostic in metastatic TNBC, with implications for metastasis, resistance, and novel therapeutic approaches.

27 April 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
SMS. Manier
S. Manier
JPJ. Park
J. Park
MCM. Capelletti
M. Capelletti
MBMark Bustoros
Mark Bustoros
SFS. S. Freeman
S. S. Freeman
IGIrene M. Ghobrial
Irene M. Ghobrial
Liquid biopsies including circulating tumor cells (CTCs) and cell-free DNA (cfDNA) have enabled minimally invasive characterization of many cancers, but are rarely analyzed together. Understanding the detectability and genomic concordance of CTCs and cfDNA may inform their use in guiding cancer precision medicine. Here, we report the detectability of cfDNA and CTCs in blood samples from 107 and 56 patients with multiple myeloma (MM), respectively. Using ultra-low pass whole-genome sequencing, we find both tumor fractions correlate with disease progression. Applying whole-exome sequencing (WES) to cfDNA, CTCs, and matched tumor biopsies, we find concordance in clonal somatic mutations (~99%) and copy number alterations (~81%) between liquid and tumor biopsies. Importantly, analyzing CTCs and cfDNA together enables cross-validation of mutations, uncovers mutations exclusive to either CTCs or cfDNA, and allows blood-based tumor profiling in a greater fraction of patients. Our study demonstrates the utility of analyzing both CTCs and cfDNA in MM.